Novel agent may be new standard, ‘launching point’ in chondrosarcoma

CHICAGO — A novel tetravalent DR5 agonist could become the first standard of care for conventional chondrosarcoma.Updated data from the first positive randomized trial in this disease showed ozekibart (INBRX-109, Inhibrx Biosciences Inc.) doubled median PFS and improved multiple other efficacy outcomes compared with placebo.